A parallel demonstration of different resins' antibody aggregate removing capability by a case study

Area of Science:

• Biopharmaceutical manufacturing
• Protein aggregation analysis
• Chromatographic purification

Background:

• Therapeutic monoclonal antibodies (mAbs) are susceptible to aggregation, which compromises drug efficacy and patient safety.
• Effective aggregate removal during downstream processing is essential for producing safe and potent mAb therapeutics.
• While hydrophobic and mixed-mode resins are common for aggregate removal, direct comparative data is limited.

Purpose of the Study:

• To evaluate and compare the aggregate removing capabilities of eight different chromatography resins.
• To provide a case study demonstrating resin performance in aggregate removal.
• To offer a broader selection of options for optimizing downstream processing of therapeutic antibodies.

Main Methods:

• A case study was designed to assess aggregate removal.
• Eight distinct chromatography resins were selected for evaluation.
• The resins represented various chromatographic types, including hydrophobic and mixed-mode interactions.

Main Results:

• The study demonstrated the aggregate removing capability of the eight evaluated resins.
• Comparative performance data was generated for different resin types.
• The findings highlight the variability in aggregate removal efficiency across different chromatographic methods.

Conclusions:

• Multiple chromatography resin options exist for therapeutic antibody aggregate removal.
• Selection of appropriate resins can enhance downstream processing flexibility and efficiency.
• This comparative study aids in optimizing purification strategies for monoclonal antibody products.